Carbon footprint of a sample of clinical trials for people with neurological disorders: cross-sectional analysis.

14 The carbon emissions of clinical trials for neurological disorders are likely to be significant because the disease burden provokes clinical trial activity, and they use a wide range of drugs, devices and outcome measures including brain imaging. 15 17 Therefore, we set out to apply the Low Carbon Clinical Trials Group’s carbon footprinting guidance to a sample of clinical trials focused on neurological disorders.

also in 476 other papers